The FDA has approved a New Drug Application for insoluble Prussian blue capsules (Radiogardase™) to treat people exposed to radiation contamination caused by harmful levels of cesium 137 or thallium. The capsules contain ferric hexacyanoferrate.
The approval of the Radiogardase™ application is part of the FDA’s continuing efforts to provide the American public with medical countermeasures in the event of a terrorist attack.
Radiogardase™ works by increasing the rate of elimination of these substances from the body. For several decades, Prussian blue has been used to enhance the excretion of cesium 137 and thallium from the body into the stool. Contamination with cesium 137 or thallium can occur through various routes, including ingestion, inhalation, or wounds, and can cause serious illness or death when high radiation doses are absorbed and delivered to critical organs. At lower doses, such contamination has been associated with the development of cancer.
Cesium 137 is widely used in industry and to treat certain cancers. Non-radioactive thallium is used in industry and as a rat poison. The radioactive form of thallium (201l) is an approved drug for use in medical imaging procedures and is very safe at low doses.
canadian pharmacy viagra
Contamination by cesium 137 is of particular concern because of its potential use as a component of conventional explosive devices containing radioactive material (“dirty bombs”). Although this radiological dispersal device is not a nuclear bomb, it can spread radioactive material and contaminate people and property.
Possible side effects include constipation and upset stomach. Treatment should begin as soon as possible after exposure to radioactive cesium or thallium. When the sources of radiation contamination are multiple or unknown, other drugs (such as potassium iodide) can be used together with Radio-gardase™.)